A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
Donald A. Richards
No relevant relationships to disclose
Fadi S. Braiteh
No relevant relationships to disclose
A. A. Garcia
No relevant relationships to disclose
Crystal Shereen Denlinger
Research Funding - Bayer; ImClone Systems; MedImmune; Merrimack Pharmaceuticals ; OncoMethylome Sciences; Pfizer
Paul R. Conkling
Research Funding - Virginia Oncology Associates
William Jeffery Edenfield
No relevant relationships to disclose
Stephen Patrick Anthony
No relevant relationships to disclose
Beth A. Hellerstedt
No relevant relationships to disclose
Robert N. Raju
No relevant relationships to disclose
Carlos Becerra
No relevant relationships to disclose
Wael A. Harb
Research Funding - Horizon Oncology Research
David A. Smith
Research Funding - Merrimack Pharmaceuticals
Charlotte Fenton McDonagh
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Kate-Lyn Kawash
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Sasha Frye
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals
Victor M. Moyo
Employment or Leadership Position - Merrimack Pharmaceuticals
Stock Ownership - Merrimack Pharmaceuticals